AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04266301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
Study NCT04266301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sabatolimab
Description: A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
Study NCT04266301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
Study NCT04266301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
Study NCT04266301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
Study NCT03673306 — intervention group
Intervention type: OTHER
Intervention: Clinical outcomes
Description: Clinical outcomes
Study NCT01006668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of propofol
Description: Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
Study NCT01091662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1600 mg
Description: 1600 mg once per day
Study NCT01091662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Description: 1200 once per day
Study NCT04279470 — intervention group
Intervention type: DRUG
Intervention: CAR T-cell and Cellular Therapies
Description: Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
Study NCT03423758 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample
Study NCT03376958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
Study NCT01532245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two lung ventilation (TLV)
Description: During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
Study NCT01532245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one lung ventilation (OLV) without PEEP
Description: During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
Study NCT01532245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)
Description: During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
Study NCT01835145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01835145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study NCT01835145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01835145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02006485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202
Description: Ublituximab IV infusion TGR-1202 oral daily dose
Study NCT02006485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202 + ibrutinib
Description: Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
Study NCT02006485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202 + bendamustine
Description: Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
Study NCT03846271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.
Study NCT04235036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
Study NCT04235036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
Study NCT03846271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.
Study NCT00994981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
Study NCT00994981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
Study NCT01146509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil hydrochloride)
Description: Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
Study NCT00162370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Injectable Suspension
Description: Activated DEFINITY 10ug/kg by bolus injection
Study NCT00606775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: 2.5-5mg/day
Study NCT01398280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid (ACA) mixed with Vanicream
Description: 25% Aminocaproic acid cream twice daily for up to 12 weeks.
Study NCT01398280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream moisturizer twice daily for up to 12 weeks
Study NCT03602651 — intervention group
Intervention type: OTHER
Intervention: Hamilton-anxiety scale (HAM-A)
Description: Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
Study NCT01750073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01750073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01750073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01750073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01750073 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT01750073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo mastectomy or breast conserving surgery
Study NCT01750073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT02848248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD123A
Description: Intravenous infusion in 3-week cycles
Study NCT02108379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinix Nasal Filters
Study NCT02803268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Study NCT02803268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose
Study NCT02803268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Study NCT02803268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02462707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
Study NCT02131779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Men's Workshops
Description: Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
Study NCT02131779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Educational Workshops
Description: One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
Study NCT01844752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 1% Gel
Description: Twice daily NVN1000 1% Gel for 12 weeks
Study NCT01844752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 4% Gel
Description: Twice daily NVN1000 4% Gel for 12 weeks
Study NCT01844752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Twice daily Vehicle Gel for 12 weeks
Study NCT03295890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needing
Description: Dry Needling
Study NCT03295890 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry Needing
Description: Dry Needling
Study NCT01951638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets
Study NCT01951638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets
Study NCT01951638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01340469 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
Study NCT01340469 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
Study NCT04304664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness- Based Intervention
Description: Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment.
Study NCT01767558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ablation / MRI
Description: All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit.
Study NCT03583749 — intervention group
Intervention type: DRUG
Intervention: Subcutaneous (SC) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
Study NCT03583749 — intervention group
Intervention type: DRUG
Intervention: Intravenous (IV) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
Study NCT04011774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLANI-REV
Description: Cognitive remediation program.
Study NCT04025034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression with ultrasonic bone removal
Description: Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
Study NCT04544657 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention for enrolled patients
Study NCT04011774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RELAXATION
Description: Stimulation with no cognitive remediation.
Study NCT02382068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given via intratympanic injection
Study NCT02382068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given via intratympanic injection
Study NCT02382068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care treatment with the following treatment course criteria:~1. Dose: > 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum
Study NCT01326026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study NCT01326026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
Study NCT02276222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg BID eFlow (CS) nebulizer
Description: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
Study NCT02276222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® 18 mcg QD Handihaler
Description: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Study NCT00838955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
Study NCT01385072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double matched sibling transplantation
Description: Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS.
Study NCT03544892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: 60-80 g total carbohydrate per day
Study NCT03544892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care diet
Description: > 150 g total carbohydrate per day
Study NCT02185625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe Delivery smartphone application
Description: The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
Study NCT00765596 — intervention group
Intervention type: OTHER
Intervention: Liquid diet for 3 days
Description: The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
Study NCT04028986 — intervention group
Intervention type: DRUG
Intervention: Ulipristal Acetate 5 MG Oral Tablet
Description: use of ulipristalacetate OR surgery before fertility treatment
Study NCT00419822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 6 Acupuncture visits
Study NCT00419822 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: 6 Acupuncture visits with sham procedure
Study NCT00419822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient to receive standard care without Acupuncture or Sham Acupuncture.
Description: Standard care
Study NCT04365582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg day 1 ; 250 mg/day for 4 days
Study NCT04365582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg x 3/day for 10 days
Study NCT04365582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir 200Mg/Ritonavir 50Mg Tab
Description: 400/100 mg (2 tablets) x 2/day for 15 days
Study NCT00158665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Description: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Study NCT02136940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076
Study NCT02136940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00649558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl Tablets 45 mg
Description: 45mg, single dose fasting
Study NCT00649558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos® Tablets 45 mg
Description: 45mg, single dose fasting
Study NCT04521855 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
Study NCT04549363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
Study NCT03360942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCC DBS
Description: Deep Brain Stimulator
Study NCT03750006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short session HIIT
Description: Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
Study NCT03736603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA Intervention Bundle 1
Description: The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation
Study NCT03736603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA Intervention Bundle 2
Description: The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App
Study NCT00693251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crush technique
Description: Crush technique
Study NCT00693251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: provisional T stenting
Description: Provisional T stenting
Study NCT01093612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: PET images performed on a GE Discovery 16 Ste PET-CT scanner
Study NCT01093612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: 15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
Study NCT01093612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative Studies